NeuralCipher AI
EN | TR
SCIENTIFIC HUB

Follow the evidence.

My reading listSource policyTürkçe sürüm
SCIENTIFIC LITERATURE · PPR

Cerebral Amyloid-β Deposition, Axial Features and Cognitive Alterations in Parkinson’s Disease Patients Treated with Bilateral STN-DBS: A Long-term Cohort Study

Cavallieri F, Fraternali A, Arnone A, Campanini I, Marti A, Gessani A, Fioravanti V, Molinari MA, Di Rauso G, Antonelli F, Rispoli V, Feletti A, Stanzani R, Damiano B, Scaltriti S, Cavazzuti L, Bardi E, Corni MG, Cavalleri F, Biagini G, Pavesi G, Lusuardi M, Budriesi C, Merlo A, Versari A, Valzania F.

· 2024-10-17

DOI: 10.20944/preprints202410.1353.v1

Check source for accessPreprintOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Objectives: To evaluate the possible long-term cerebral deposition of amyloid-β in PD patients treated with subthalamic nucleus deep brain stimulation (STN-DBS) and its possible influence on axial and cognitive variables. Methods: Consecutive PD patients treated with bilateral STN-DBS with a long-term follow-up were included. Amyloid-β deposition was evaluated postoperatively through a 18F-flutemetamol positron emission tomography (PET) study. Axial symptoms have been assessed using a standardized clinical-instrumental approach. Speech was assessed by perceptual and acoustic analysis while gait by means of the instrumented timed up and go test (iTUG). Motor severity was evaluated applying the UPDRS part III score and subscores while cognitive functions through a complete neuropsychological assessment. Different stimulation and drug conditions were assessed: on-stimulation/off-medication, off-stimulation/off-medication, on-stimulation/on-medication conditions (single and dual task). Results: 19 PD patients (male: 11; age: 63.52 years; on-stimulation/on-medication UPDRS-III: 17.05) with a five-year postoperative follow-up were included. Amyloid-β deposition was found in 21% of patients (4/19) with a prevalent involvement of prefrontal, limbic and parietal areas. Compared with patients without amyloid-β deposition, PD patients with positive 18F-flutemetamol PET study showed higher preoperative UPDRS-I (p=.037) score and lower postoperative Raven's matrices scores (p=.05). Conclusions: Our results suggest that in the long-term after STN-DBS a significant percentage of PD patients may present brain amyloid-β deposition. However, larger samples are needed to evaluate the possible role of amyloid-β deposition in the development of axial and cognitive alterations after surgery.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.